Zentek Ltd. (TSE:ZEN) has released an update.
Zentek Ltd. and its subsidiary Triera Biosciences Ltd. have reported promising initial results in the development of a prophylactic and therapeutic agent for avian influenza, specifically the H5N1 strain. The novel multivalent aptamer technology showcased higher binding affinity than previous treatments and has been earmarked for immediate in vivo testing due to the global urgency of the recent H5N1 outbreaks. A provisional patent has been filed for this potentially groundbreaking influenza virus-targeting aptamer.
For further insights into TSE:ZEN stock, check out TipRanks’ Stock Analysis page.
